Gällande vårdprogram huvud- och halscancer

Fastställt av Regionala cancercentrum i samverkan 2015-08-25.

15. Referenser

    1. Internationell statistisk klassifikation av sjukdomar och relaterade hälsoproblem – Systematisk förteckning, svensk version 2011 (ICD-10-SE) www.socialstyrelsen.se/klassifikationer.
    2. Jensen AR, Nellemann HM, Overgaard J. Tumor progression in waiting time for radiotherapy in head and neck cancer. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2007;84(1):5-10.
    3. Waaijer A, Terhaard CH, Dehnad H, Hordijk GJ, van Leeuwen MS, Raaymakers CP, et al. Waiting times for radiotherapy: consequences of volume increase for the TCP in oropharyngeal carcinoma. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2003;66(3):271-6.
    4. Chen Z, King W, Pearcey R, Kerba M, Mackillop WJ. The relationship between waiting time for radiotherapy and clinical outcomes: a systematic review of the literature. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2008;87(1):3-16.
    5. Leslie H. Sobin (Editor), Mary K. Gospodarowicz (Editor), Christian Wittekind (Editor) TNM Classification of Malignant Tumours, 7th Edition. November 2009, Wiley-Blackwell, ISBN 978-1-4443-3241-4. ed.
    6. www.socialstyrelsen.se/statistik/statistikdatabas.
    7. SweHNCR 2008-2012.
    8. www.globocan.iarc.fr.
    9. Annertz K, Anderson H, Biorklund A, Moller T, Kantola S, Mork J, et al. Incidence and survival of squamous cell carcinoma of the tongue in Scandinavia, with special reference to young adults. International journal of cancer Journal international du cancer. 2002;101(1):95-9.
    10. Schantz SP, Yu GP. Head and neck cancer incidence trends in young Americans, 1973-1997, with a special analysis for tongue cancer. Archives of otolaryngology--head & neck surgery. 2002;128(3):268-74.
    11. Bleyer A. Cancer of the oral cavity and pharynx in young females: increasing incidence, role of human papilloma virus, and lack of survival improvement. Seminars in oncology. 2009;36(5):451-9.
    12. Brown LM, Check DP, Devesa SS. Oral cavity and pharynx cancer incidence trends by subsite in the United States: changing gender patterns. Journal of oncology. 2012;2012:649498.
    13. Hammarstedt L, Dahlstrand H, Lindquist D, Onelov L, Ryott M, Luo J, et al. The incidence of tonsillar cancer in Sweden is increasing. Acta oto-laryngologica. 2007;127(9):988-92.
    14. Attner P, Du J, Nasman A, Hammarstedt L, Ramqvist T, Lindholm J, et al. The role of human papillomavirus in the increased incidence of base of tongue cancer. International journal of cancer Journal international du cancer. 2010;126(12):2879-84.
    15. Hammarstedt L, Lindquist D, Dahlstrand H, Romanitan M, Dahlgren LO, Joneberg J, et al. Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer. International journal of cancer Journal international du cancer. 2006;119(11):2620-3.
    16. Chaturvedi AK. Epidemiology and clinical aspects of HPV in head and neck cancers. Head and neck pathology. 2012;6 Suppl 1:S16-24.
    17. Jia WH, Qin HD. Non-viral environmental risk factors for nasopharyngeal carcinoma: a systematic review. Seminars in cancer biology. 2012;22(2):117-26.
    18. Hakulinen T, Tryggvadottir L, Gislum M, Storm HH, Bray F, Klint A, et al. Trends in the survival of patients diagnosed with cancers of the lip, oral cavity, and pharynx in the Nordic countries 1964-2003 followed up to the end of 2006. Acta oncologica. 2010;49(5):561-77.
    19. www-dep.iarc.fr/NORDCAN/SW/frame.asp).
    20. Carvalho AL, Nishimoto IN, Califano JA, Kowalski LP. Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. International journal of cancer Journal international du cancer. 2005;114(5):806-16.
    21. Pulte D, Brenner H. Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis. The oncologist. 2010;15(9):994-1001.
    22. Tuyns AJ, Esteve J, Raymond L, Berrino F, Benhamou E, Blanchet F, et al. Cancer of the larynx/hypopharynx, tobacco and alcohol: IARC international case-control study in Turin and Varese (Italy), Zaragoza and Navarra (Spain), Geneva (Switzerland) and Calvados (France). International journal of cancer Journal international du cancer. 1988;41(4):483-91.
    23. Lewin F, Norell SE, Johansson H, Gustavsson P, Wennerberg J, Biorklund A, et al. Smoking tobacco, oral snuff, and alcohol in the etiology of squamous cell carcinoma of the head and neck: a population-based case-referent study in Sweden. Cancer. 1998;82(7):1367-75.
    24. Tredaniel J, Boffetta P, Saracci R, Hirsch A. Environmental tobacco smoke and the risk of cancer in adults. European journal of cancer. 1993;29A(14):2058-68.
    25. Blot WJ, McLaughlin JK, Winn DM, Austin DF, Greenberg RS, Preston-Martin S, et al. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer research. 1988;48(11):3282-7.
    26. Franceschi S, Talamini R, Barra S, Baron AE, Negri E, Bidoli E, et al. Smoking and drinking in relation to cancers of the oral cavity, pharynx, larynx, and esophagus in northern Italy. Cancer research. 1990;50(20):6502-7.
    27. Rosenquist K, Wennerberg J, Schildt EB, Bladstrom A, Goran Hansson B, Andersson G. Oral status, oral infections and some lifestyle factors as risk factors for oral and oropharyngeal squamous cell carcinoma. A population-based case-control study in southern Sweden. Acta oto-laryngologica. 2005;125(12):1327-36.
    28. Du J, Nordfors C, Ahrlund-Richter A, Sobkowiak M, Romanitan M, Nasman A, et al. Prevalence of oral human papillomavirus infection among youth, Sweden. Emerging infectious diseases. 2012;18(9):1468-71.
    29. de Vries N, Van der Waal I, Snow GB. Multiple primary tumours in oral cancer. International journal of oral and maxillofacial surgery. 1986;15(1):85-7.
    30. Terhaard CH, Hordijk GJ, van den Broek P, de Jong PC, Snow GB, Hilgers FJ, et al. T3 laryngeal cancer: a retrospective study of the Dutch Head and Neck Oncology Cooperative Group: study design and general results. Clinical otolaryngology and allied sciences. 1992;17(5):393-402.
    31. Morris LG, Sikora AG, Hayes RB, Patel SG, Ganly I. Anatomic sites at elevated risk of second primary cancer after an index head and neck cancer. Cancer causes & control : CCC. 2011;22(5):671-9.
    32. Neville BW, Day TA. Oral cancer and precancerous lesions. CA: a cancer journal for clinicians. 2002;52(4):195-215.
    33. Axell T. A prevalence study of oral mucosal lesions in an adult Swedish population. Odontologisk revy Supplement. 1976;36:1-103.
    34. Einhorn J, Wersall J. Incidence of oral carcinoma in patients with leukoplakia of the oral mucosa. Cancer. 1967;20(12):2189-93.
    35. Roed-Petersen B. Cancer development inoral laukoplakia: Follow-up of 331 patients. J Dent Res. 1971;50:711.
    36. Gonzalez-Moles MA, Scully C, Gil-Montoya JA. Oral lichen planus: controversies surrounding malignant transformation. Oral diseases. 2008;14(3):229-43.
    37. Govindaraj S, Wang H. Does human papilloma virus play a role in sinonasal inverted papilloma? Current opinion in otolaryngology & head and neck surgery. 2014;22(1):47-51.
    38. McLaughlin JK, Gridley G, Block G, Winn DM, Preston-Martin S, Schoenberg JB, et al. Dietary factors in oral and pharyngeal cancer. Journal of the National Cancer Institute. 1988;80(15):1237-43.
    39. La Vecchia C, Tavani A, Franceschi S, Levi F, Corrao G, Negri E. Epidemiology and prevention of oral cancer. Oral oncology. 1997;33(5):302-12.
    40. Chernok R. Chernok RD, Morphological features of conventional squamous cell carcinoma of the orofarynx: “Keratinizing” and “Non-keratinizing” histologic types as the basis for a consistent classification system. Head and Neck Path. 2012;6:541-7.
    41. Tabor MP, Brakenhoff RH, Ruijter-Schippers HJ, Kummer JA, Leemans CR, Braakhuis BJ. Genetically altered fields as origin of locally recurrent head and neck cancer: a retrospective study. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004;10(11):3607-13.
    42. Venuti A, Paolini F. HPV detection methods in head and neck cancer. Head and neck pathology. 2012;6 Suppl 1:S63-74.
    43. Westra WH. The morphologic profile of HPV-related head and neck squamous carcinoma: implications for diagnosis, prognosis, and clinical management. Head and neck pathology. 2012;6 Suppl 1:S48-54.
    44. Martinez Barbero JP et al Utility of MRI Diffusion Techniques in the Evaluation of Tumours of the Head and Neck. Cancers 2013, 5, 857-889.
    45. Gupta T et al Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and metaanalysis. European Journal of Nuclear Medicine & Molecular Imaging 2011, 8, (11) 2083-2095.
    46. Escott EJ. Role of positron emission tomography/computed tomography (PET/CT) in head and neck cancer. Radiologic clinics of North America. 2013;51(5):881-93.
    47. Liao LJ, Lo WC, Hsu WL, Wang CT, Lai MS. Detection of cervical lymph node metastasis in head and neck cancer patients with clinically N0 neck-a meta-analysis comparing different imaging modalities. BMC cancer. 2012;12:236.
    48. Broglie MA, Stoeckli SJ. Relevance of sentinel node procedures in head and neck squamous cell carcinoma. The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine. 2011;55(5):509-20.
    49. Robbins KT, Clayman G, Levine PA, Medina J, Sessions R, Shaha A, et al. Neck dissection classification update: revisions proposed by the American Head and Neck Society and the American Academy of Otolaryngology-Head and Neck Surgery. Archives of otolaryngology--head & neck surgery. 2002;128(7):751-8.
    50. Marks LB, Yorke ED, Jackson A, Ten Haken RK, Constine LS, Eisbruch A, et al. Use of normal tissue complication probability models in the clinic. International journal of radiation oncology, biology, physics. 2010;76(3 Suppl):S10-9.
    51. Sher T, Miller KC, Lawrence D, Whitworth A, Hernandez-Ilizaliturri F, Czuczman MS, et al. Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. Leukemia & lymphoma. 2010;51(1):85-8.
    52. Tanvetyanon T, Padhya T, McCaffrey J, Zhu W, Boulware D, Deconti R, et al. Prognostic factors for survival after salvage reirradiation of head and neck cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009;27(12):1983-91.
    53. Pignon JP, le Maitre A, Maillard E, Bourhis J, Group M-NC. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2009;92(1):4-14.
    54. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. The New England journal of medicine. 2008;359(11):1116-27.
    55. Blanchard P, Bourhis J, Lacas B, Posner MR, Vermorken JB, Hernandez JJ, et al. Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013;31(23):2854-60.
    56. Lee AW, Lin JC, Ng WT. Current management of nasopharyngeal cancer. Seminars in radiation oncology. 2012;22(3):233-44.
    57. Blanchard P, Baujat B, Holostenco V, Bourredjem A, Baey C, Bourhis J, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2011;100(1):33-40.
    58. Machtay M, Moughan J, Trotti A, Garden AS, Weber RS, Cooper JS, et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008;26(21):3582-9.
    59. Corry J, Peters LJ, Rischin D. Optimising the therapeutic ratio in head and neck cancer. The Lancet Oncology. 2010;11(3):287-91.
    60. Baujat B, Audry H, Bourhis J, Chan AT, Onat H, Chua DT, et al. Chemotherapy as an adjunct to radiotherapy in locally advanced nasopharyngeal carcinoma. The Cochrane database of systematic reviews. 2006(4):CD004329.
    61. Rutten H, Pop LA, Janssens GO, Takes RP, Knuijt S, Rooijakkers AF, et al. Long-term outcome and morbidity after treatment with accelerated radiotherapy and weekly cisplatin for locally advanced head-and-neck cancer: results of a multidisciplinary late morbidity clinic. International journal of radiation oncology, biology, physics. 2011;81(4):923-9.
    62. Watkins JM, Zauls AJ, Wahlquist AH, Shirai K, Garrett-Mayer E, Gillespie MB, et al. Low-dose weekly platinum-based chemoradiation for advanced head and neck cancer. The Laryngoscope. 2010;120(2):236-42.
    63. Ho KF, Swindell R, Brammer CV. Dose intensity comparison between weekly and 3-weekly Cisplatin delivered concurrently with radical radiotherapy for head and neck cancer: a retrospective comparison from New Cross Hospital, Wolverhampton, UK. Acta oncologica. 2008;47(8):1513-8.
    64. Gupta T, Agarwal JP, Ghosh-Laskar S, Parikh PM, D'Cruz AK, Dinshaw KA. Radical radiotherapy with concurrent weekly cisplatin in loco-regionally advanced squamous cell carcinoma of the head and neck: a single-institution experience. Head & neck oncology. 2009;1:17.
    65. Steinmann D, Cerny B, Karstens JH, Brenner M Chemotherapy with Weekly Cisplatin 40mg/m2 in 103 Head-and-Neck Cancer patients. A cumulative Dose –Effect Analysis Strahlentherapie und Onkologie 2009;185:682-8 
    66. Homma A, Inamura N, Oridate N, Suzuki S, Hatakeyama H, Mizumachi T, et al. Concomitant weekly cisplatin and radiotherapy for head and neck cancer. Japanese journal of clinical oncology. 2011;41(8):980-6.
    67. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer research. 2002;62(24):7350-6.
    68. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. The Lancet Oncology. 2010;11(1):21-8.
    69. Walsh L, Gillham C, Dunne M, Fraser I, Hollywood D, Armstrong J, et al. Toxicity of cetuximab versus cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer (LAHNSCC). Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2011;98(1):38-41.
    70. Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Sherman EJ, Weber RS, et al. Randomized Phase III Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Stage III to IV Head and Neck Carcinoma: RTOG 0522. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014.
    71. Levy AR, Johnston KM, Sambrook J, Donato B, Penrod JR, Corral M, et al. Indirect comparison of the efficacy of cetuximab and cisplatin in squamous cell carcinoma of the head and neck. Current medical research and opinion. 2011;27(12):2253-9.
    72. Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head & neck. 2005;27(10):843-50.
    73. Silander E, Nyman J, Bove M, Johansson L, Larsson S, Hammerlid E. The use of prophylactic percutaneous endoscopic gastrostomy and early enteral feeding in patients with advanced head and neck cancer-A prospectivelongitudinal study. E-SPEN, the European e-journal of Clincical Nutrition and metabolism 5 (2010) e166-e172.
    74. Langendijk JA, Doornaert P, Verdonck-de Leeuw IM, Leemans CR, Aaronson NK, Slotman BJ. Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008;26(22):3770-6.
    75. Denk DM, Swoboda H, Schima W, Eibenberger K. Prognostic factors for swallowing rehabilitation following head and neck cancer surgery. Acta oto-laryngologica. 1997;117(5):769-74.
    76. Silander E, Nyman J, Bove M, Johansson L, Larsson S, Hammerlid E. Impact of prophylactic percutaneous endoscopic gastrostomy on malnutrition and quality of life in patients with head and neck cancer: a randomized study. Head & neck. 2012;34(1):1-9.
    77. Curran D, Giralt J, Harari PM, Ang KK, Cohen RB, Kies MS, et al. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007;25(16):2191-7.
    78. Johnson J, van As-Brooks CJ, Fagerberg-Mohlin B, Finizia C. Trismus in head and neck cancer patients in Sweden: incidence and risk factors. Medical science monitor : international medical journal of experimental and clinical research. 2010;16(6):CR278-82.
    79. Bensadoun RJ, Riesenbeck D, Lockhart PB, Elting LS, Spijkervet FK, Brennan MT, et al. A systematic review of trismus induced by cancer therapies in head and neck cancer patients. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2010;18(8):1033-8.
    80. Ichimura K, Tanaka T. Trismus in patients with malignant tumours in the head and neck. The Journal of laryngology and otology. 1993;107(11):1017-20.
    81. Kamstra JI, Roodenburg JL, Beurskens CH, Reintsema H, Dijkstra PU. TheraBite exercises to treat trismus secondary to head and neck cancer. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2013;21(4):951-7.
    82. Dijkstra PU, Sterken MW, Pater R, Spijkervet FK, Roodenburg JL. Exercise therapy for trismus in head and neck cancer. Oral oncology. 2007;43(4):389-94.
    83. Bak M, Jacobson AS, Buchbinder D, Urken ML. Contemporary reconstruction of the mandible. Oral oncology. 2010;46(2):71-6.
    84. Lambade PN, Lambade D, Goel M. Osteoradionecrosis of the mandible: a review. Oral and maxillofacial surgery. 2013;17(4):243-9.
    85. Wahl MJ. Osteoradionecrosis prevention myths. International journal of radiation oncology, biology, physics. 2006;64(3):661-9.
    86. Nabil S, Samman N. Incidence and prevention of osteoradionecrosis after dental extraction in irradiated patients: a systematic review. International journal of oral and maxillofacial surgery. 2011;40(3):229-43.
    87. Sjogren A, Lynoe N, Leijonhufvud M, Sigvant B. [Blow out hemorrhage in the head and neck region in practice. Suggestions for what we can, may and should do]. Lakartidningen. 2014;111(8):331-3.
    88. Kansy K, Thiele O, Freier K. The role of human papillomavirus in oral squamous cell carcinoma: myth and reality. Oral and maxillofacial surgery. 2014;18(2):165-72.
    89. Tshering Vogel DW, Zbaeren P, Thoeny HC. Cancer of the oral cavity and oropharynx. Cancer imaging : the official publication of the International Cancer Imaging Society. 2010;10:62-72.
    90. Rumboldt Z, Day TA, Michel M. Imaging of oral cavity cancer. Oral oncology. 2006;42(9):854-65.
    91. Weissman JL, Carrau RL. "Puffed-cheek" CT improves evaluation of the oral cavity. AJNR American journal of neuroradiology. 2001;22(4):741-4.
    92. Furness S, Glenny AM, Worthington HV, Pavitt S, Oliver R, Clarkson JE, et al. Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy. The Cochrane database of systematic reviews. 2011(4):CD006386.
    93. Bessell A, Glenny AM, Furness S, Clarkson JE, Oliver R, Conway DI, et al. Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment. The Cochrane database of systematic reviews. 2011(9):CD006205.
    94. Glenny AM, Furness S, Worthington HV, Conway DI, Oliver R, Clarkson JE, et al. Interventions for the treatment of oral cavity and oropharyngeal cancer: radiotherapy. The Cochrane database of systematic reviews. 2010(12):CD006387.
    95. Johnson RE, Sigman JD, Funk GF, Robinson RA, Hoffman HT. Quantification of surgical margin shrinkage in the oral cavity. Head & neck. 1997;19(4):281-6.
    96. Friedman M, Mafee MF, Pacella BL, Jr., Strorigl TL, Dew LL, Toriumi DM. Rationale for elective neck dissection in 1990. The Laryngoscope. 1990;100(1):54-9.
    97. Ross GL, Soutar DS, MacDonald DG, Shoaib T, Camilleri IG, Robertson AG. Improved staging of cervical metastases in clinically node-negative patients with head and neck squamous cell carcinoma. Annals of surgical oncology. 2004;11(2):213-8.
    98. Stoeckli SJ, Alkureishi LW, Ross GL. Sentinel node biopsy for early oral and oropharyngeal squamous cell carcinoma. European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies. 2009;266(6):787-93.
    99. Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre JL, Greiner RH, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. The New England journal of medicine. 2004;350(19):1945-52.
    100. Pathology and Genetics Head and Neck Tumours WHO Classification 2003 ISBN 9283224175.
    101. Mancuso et al Head and Neck Radiology, Lippincott-Wilkins, 2011.
    102. Trotta BM, Pease CS, Rasamny JJ, Raghavan P, Mukherjee S. Oral cavity and oropharyngeal squamous cell cancer: key imaging findings for staging and treatment planning. Radiographics : a review publication of the Radiological Society of North America, Inc. 2011;31(2):339-54.
    103. Iyer NG, Nixon IJ, Palmer F, Kim L, Whitcher M, Katabi N, et al. Surgical management of squamous cell carcinoma of the soft palate: factors predictive of outcome. Head & neck. 2012;34(8):1071-80.
    104. Espinosa Restrepo F, Martinez Capoccioni G, Martin Martin C. T1-T2 squamous cell carcinoma of the uvula: a little big enemy. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery. 2012;146(1):81-7.
    105. de Almeida JR, Genden EM. Robotic surgery for oropharynx cancer: promise, challenges, and future directions. Current oncology reports. 2012;14(2):148-57.
    106. White H, Ford S, Bush B, Holsinger FC, Moore E, Ghanem T, et al. Salvage surgery for recurrent cancers of the oropharynx: comparing TORS with standard open surgical approaches. JAMA otolaryngology-- head & neck surgery. 2013;139(8):773-8.
    107. Wang WY, Twu CW, Chen HH, Jiang RS, Wu CT, Liang KL, et al. Long-term survival analysis of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA levels. Cancer. 2013;119(5):963-70.
    108. Chong V et al; Neoplasms of the nasopharynx, (i Hermans; Head an Neck Cancer Imaging, Springer 2008).
    109. King AD, Bhatia KS. Magnetic resonance imaging staging of nasopharyngeal carcinoma in the head and neck. World journal of radiology. 2010;2(5):159-65.
    110. Abdel Khalek Abdel Razek A, King A. MRI and CT of nasopharyngeal carcinoma. AJR American journal of roentgenology. 2012;198(1):11-8.
    111. King AD, Ma BB, Yau YY, Zee B, Leung SF, Wong JK, et al. The impact of 18F-FDG PET/CT on assessment of nasopharyngeal carcinoma at diagnosis. The British journal of radiology. 2008;81(964):291-8.
    112. Yoo J, Lacchetti C, Hammond JA, Gilbert RW, Head, Neck Cancer Disease Site G. Role of endolaryngeal surgery (with or without laser) versus radiotherapy in the management of early (T1) glottic cancer: A systematic review. Head & neck. 2013.
    113. Comoretto M, Balestreri L, Borsatti E, Cimitan M, Franchin G, Lise M. Detection and restaging of residual and/or recurrent nasopharyngeal carcinoma after chemotherapy and radiation therapy: comparison of MR imaging and FDG PET/CT. Radiology. 2008;249(1):203-11.
    114. Lee AW, Tung SY, Chua DT, Ngan RK, Chappell R, Tung R, et al. Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma. Journal of the National Cancer Institute. 2010;102(15):1188-98.
    115. Wei WI, Lam KH, Sham JS. New approach to the nasopharynx: the maxillary swing approach. Head & neck. 1991;13(3):200-7.
    116. Brandwein-Gensler M, Teixeira MS, Lewis CM, Lee B, Rolnitzky L, Hille JJ, et al. Oral squamous cell carcinoma: histologic risk assessment, but not margin status, is strongly predictive of local disease-free and overall survival. The American journal of surgical pathology. 2005;29(2):167-78.
    117. Weing B. Atlas of head and neck pathology. 2nd ed: Saunders, Elsevier; 2008.
    118. Wycliffe ND, Grover RS, Kim PD, Simental A, Jr. Hypopharyngeal cancer. Topics in magnetic resonance imaging : TMRI. 2007;18(4):243-58.
    119. Becker M, Burkhardt K, Dulguerov P, Allal A. Imaging of the larynx and hypopharynx. European journal of radiology. 2008;66(3):460-79.
    120. Joshi VM, Wadhwa V, Mukherji SK. Imaging in laryngeal cancers. The Indian journal of radiology & imaging. 2012;22(3):209-26.
    121. Becker M, Zbaren P, Casselman JW, Kohler R, Dulguerov P, Becker CD. Neoplastic invasion of laryngeal cartilage: reassessment of criteria for diagnosis at MR imaging. Radiology. 2008;249(2):551-9.
    122. Seifert G, Brocheriou C, Cardesa A, Eveson JW. WHO International Histological Classification of Tumours. Tentative Histological Classification of Salivary Gland Tumours. Pathology, research and practice. 1990;186(5):555-81.
    123. Seethala RR. An update on grading of salivary gland carcinomas. Head and neck pathology. 2009;3(1):69-77.
    124. Brandwein MS, Ivanov K, Wallace DI, Hille JJ, Wang B, Fahmy A, et al. Mucoepidermoid carcinoma: a clinicopathologic study of 80 patients with special reference to histological grading. The American journal of surgical pathology. 2001;25(7):835-45.
    125. McHugh JB, Visscher DW, Barnes EL. Update on selected salivary gland neoplasms. Archives of pathology & laboratory medicine. 2009;133(11):1763-74.
    126. Ettl T, Schwarz-Furlan S, Gosau M, Reichert TE. Salivary gland carcinomas. Oral and maxillofacial surgery. 2012;16(3):267-83.
    127. Bradley PJ. General Epidemiologyof Salivary Gland Tumours (benign and malignant) In: McGurk MC, Cscarini L eds. Controversies in the management of Salivary Gland Disease. Oxford University Press, 2012.
    128. Valstar MH, van den Brekel MW, Smeele LE. Interpretation of treatment outcome in the clinically node-negative neck in primary parotid carcinoma: a systematic review of the literature. Head & neck. 2010;32(10):1402-11.
    129. Bhattacharyya N, Fried MP. Nodal metastasis in major salivary gland cancer: predictive factors and effects on survival. Archives of otolaryngology--head & neck surgery. 2002;128(8):904-8.
    130. Laurie SA, Licitra L. Systemic therapy in the palliative management of advanced salivary gland cancers. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006;24(17):2673-8.
    131. Ali S, Palmer FL, Yu C, DiLorenzo M, Shah JP, Kattan MW, et al. Postoperative nomograms predictive of survival after surgical management of malignant tumors of the major salivary glands. Annals of surgical oncology. 2014;21(2):637-42.
    132. Jangard M, Hansson J, Ragnarsson-Olding B. Primary sinonasal malignant melanoma: a nationwide study of the Swedish population, 1960-2000. Rhinology. 2013;51(1):22-30.
    133. Acheson ED, Cowdell RH, Hadfield E, Macbeth RG. Nasal cancer in woodworkers in the furniture industry. British medical journal. 1968;2(5605):587-96.
    134. Lund VJ, Stammberger H, Nicolai P, Castelnuovo P, Beal T, Beham A, et al. European position paper on endoscopic management of tumours of the nose, paranasal sinuses and skull base. Rhinology Supplement. 2010(22):1-143.
    135. Cantu G, Bimbi G, Miceli R, Mariani L, Colombo S, Riccio S, et al. Lymph node metastases in malignant tumors of the paranasal sinuses: prognostic value and treatment. Archives of otolaryngology--head & neck surgery. 2008;134(2):170-7.
    136. Singh N, Eskander A, Huang SH, Curtin H, Bartlett E, Vescan A, et al. Imaging and resectability issues of sinonasal tumors. Expert review of anticancer therapy. 2013;13(3):297-312.
    137. Head and neck imaging. Som P, Curtin H, editors: Elsevier; 2011.
    138. Diagnostic imaging head and neck, R Harnsberger editor, Amirsys, Salt Lake City 2010.
    139. Bjork-Eriksson T, Mercke C, Petruson B, Ekholm S. Potential impact on tumor control and organ preservation with cisplatin and 5-fluorouracil for patients with advanced tumors of the paranasal sinuses and nasal fossa. A prospective pilot study. Cancer. 1992;70(11):2615-20.
    140. Xu CC, Dziegielewski PT, McGaw WT, Seikaly H. Sinonasal undifferentiated carcinoma (SNUC): the Alberta experience and literature review. Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale. 2013;42:2.
    141. Goldenberg D, Sciubba J, Koch WM. Cystic metastasis from head and neck squamous cell cancer: a distinct disease variant? Head & neck. 2006;28(7):633-8.
    142. Grau C, Johansen LV, Jakobsen J, Geertsen P, Andersen E, Jensen BB. Cervical lymph node metastases from unknown primary tumours. Results from a national survey by the Danish Society for Head and Neck Oncology. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2000;55(2):121-9.
    143. Johansen J, Petersen H, Godballe C, Loft A, Grau C. FDG-PET/CT for detection of the unknown primary head and neck tumor. The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine. 2011;55(5):500-8.
    144. Zollinger LV, Wiggins RH. A head and neck radiologist's perspective on best practices for the usage of PET/CT scans for the diagnosis and treatment of head and neck cancers. Archives of otolaryngology--head & neck surgery. 2012;138(8):754-8.
    145. Wong WL, Sonoda LI, Gharpurhy A, Gollub F, Wellsted D, Goodchild K, et al. 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the assessment of occult primary head and neck cancers--an audit and review of published studies. Clinical oncology. 2012;24(3):190-5.